ArticleMayo Clinic proceedings. Innovations, quality & outcomes2021
Successful Treatment of Pembrolizumab-Induced Severe Capillary Leak Syndrome and Lymphatic Capillary Dysfunction.
Article in Mayo Clinic proceedings. Innovations, quality & outcomes, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 22 citations in OpenAlex.
- Overlapping Toxicities of Pembrolizumab and Lenvatinib: A Case of Capillary Leak Syndrome with Severe Erythroblastosis.Current oncology (Toronto, Ont.) · 2026Article
- Case Report: Pembrolizumab unmasks a capillary leak syndrome with chylothorax in early TNBC.Frontiers in oncology · 2026Article
- Pembrolizumab-Induced Capillary Leak Syndrome: A Rare but Life-Threatening Immune-Related Adverse Event.Cureus · 2025Article
- Immunotherapy-associated capillary leak syndrome in endometrial cancer: a case report and review of the literature.Gynecologic oncology reports · 2025Article
- Pembrolizumab-Induced Simultaneous and Refractory Systemic Capillary Leak and Cytokine Release Syndromes: A Case Report.Current oncology (Toronto, Ont.) · 2025Article
- Acute kidney injury following CAR-T cell therapy: a nephrologist's perspective.Clinical kidney journal · 2025Review
- Nivolumab-Induced Chylothorax in A Patient with Advanced Gastric Adenocarcinoma.European journal of case reports in internal medicine · 2025Article
- Article
- Severe late onset capillary leak syndrome post allo-HSCT successfully treated by bevacizumab: a case report.Frontiers in medicine · 2024Article
- A Case of Polyserositis, Chylous Ascites and Hepatitis Induced by Immune Checkpoint Inhibitors.European journal of case reports in internal medicine · 2024Article
- Systemic Capillary Leak Syndrome (SCLS) Presentation in Patients Receiving Anti-cancer Treatments.Cureus · 2023Review
- Bilateral choroidal effusions and angle closure in the setting of systemic capillary leak syndrome from HLA-directed vaccine and pembrolizumab therapy for squamous cell carcinoma.American journal of ophthalmology case reports · 2023Article
- Case report: Clinical experience of treating pembrolizumab-induced systemic capillary leak syndrome (SCLS) in one patient with metastatic gastroesophageal junction squamous cell carcinoma.Pathology oncology research : POR · 2023Article
- What Is Happening to This Patient With a Rare Leukemia?Journal of the advanced practitioner in oncology · 2022Article
- Anticancer Drug-Induced Capillary Leak Syndrome.Kidney international reports · 2022Review
- Nivolumab-induced capillary leak syndrome associated with chylothorax in a melanoma patient: A case report and review of the literature.Frontiers in oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although capillary leak syndrome has a high mortality rate, its trigger, diagnosis, and treatment remain a challenge to clinicians because of the poor understanding of its mechanism and lack of treatment guidelines. With the extended use of immune checkpoint inhibitors in modern oncology, immune checkpoint inhibitor-associated immune-related adverse events have also expanded. We present a case of pembrolizumab-induced capillary leak syndrome and lymphatic capillary dysfunction in which the patient had an excellent clinical response to a tailored treatment strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.